<DOC>
	<DOCNO>NCT01469793</DOCNO>
	<brief_summary>This multicenter , open-label , dose-escalating study ass safety , tolerability , pharmacokinetics DMOT4039A participant unresectable pancreatic platinum-resistant ovarian cancer . Cohorts participant receive multiple ascend intravenous dos DMOT4039A .</brief_summary>
	<brief_title>A Study DMOT4039A Participants With Unresectable Pancreatic Platinum-Resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histologically document , incurable , locally advanced metastatic disease standard therapy exist , consist one following : Unresectable pancreatic ductal adenocarcinoma platinumresistant ovarian cancer Measureable disease , define least one bidimensionally measurable nonlymph node lesion great equal ( &gt; /= ) 1 centimeter ( cm ) longaxis diameter spiral compute tomography ( CT ) scan least one bidimensionally measurable lymph node measure &gt; /= 1.5 cm shortaxis diameter spiral CT scan Adequate hematological , renal liver function Treatment antitumor therapy , include chemotherapy , biologic , experimental hormonal therapy , within 4 week prior Day 1 Known active infection Current Grade &gt; /= 2 toxicity ( except alopecia , anorexia fatigue ) prior therapy Grade &gt; /= 2 neuropathy Untreated active cerebral nervous system metastases Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>